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Abstract: Neurofibrillary tangles, which are major pathological hallmarks of Alzheimer’s disease (AD), are composed
of paired helical filaments (PHFs) containing hyperphosphorylated tau. Specific kinases regulate tau phosphorylation
and are closely linked to the pathogenesis of AD. We have characterized a human tau-tubulin kinase 1 (TTBK1) gene
located on chromosome 6p21.1. TTBK1 is a serine/threonine/tyrosine kinase that is conserved among species and
belongs to the casein kinase 1 superfamily. It is specifically expressed in the brain, especially in the cytoplasm of
cortical and hippocampal neurons. TTBK1 phosphorylates tau proteins in both a Mg2+- and a Mn2+-dependent manner.
Phosphopeptide mapping and immunoblotting analysis confirmed a direct tau phosphorylation by TTBK1 at Ser198,
Ser199, Ser202 and Ser422, which are also phosphorylated in PHFs. TTBK1 also induces tau aggregation in human
neuronal cells in a dose-dependent manner. We conclude that TTBK1 is a neuron-specific dual kinase involved in tau
phosphorylation at AD-related sites and is also associated with tau aggregation.
Keywords: aggregation, Alzheimer’s disease, molecular cloning, phosphorylation, protein kinase, tau protein.

Neurofibrillary tangles (NFTs) are pathologic hallmarks
of Alzheimer’s disease (AD) and other neurodegenerative
diseases called ‘tauopathies’ (Lee et al. 2001). NFTs contain abnormal paired helical filaments (PHFs), of which
the primary component is hyperphosphorylated tau protein (PHF-tau) (Grundke-Iqbal et al. 1986; Buee et al.
2000; Lee et al. 2001). NFTs are also found in the brain
of patients with frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), a neurodegenerative disease caused by autosomal dominant mutations
in the tau gene (Hutton et al. 1998). Because phosphorylation of specific sites of the tau gene reduces its affinity for microtubules, the phosphorylation of tau is a critical
modification required for NFT formation (Biernat et al.
1993; Bramblett et al. 1993) and the induction of self-aggregation (Alonso et al. 1996; Alonso et al. 2001).
A number of protein kinases have been studied in
investigating the molecular mechanism of tau phosphorylation (Planel et al. 2002). Among them, the glycogen synthase kinase 3β (GSK3β) and cyclin-depen-

dent protein kinase CDK5/p25 complexes are well
characterized. They have been biochemically isolated
as kinases that can phosphorylate tau proteins at multiple Ser/Thr residues found in PHF-tau, and their expressions are up-regulated in the brain of patients with
AD (Ishiguro et al. 1992; Arioka et al. 1993; Imahori
and Uchida 1997; Patrick et al. 1999). Over-expression
of CDK5 activator p25 in mouse and GSK3β in fly enhances tau aggregation in vivo (Jackson et al. 2002;
Abbreviations: Abs, antibodies; AD, Alzheimer’s disease;
CDK, cyclin-dependent protein kinase; CK, casein kinase; Cq,
chloroquine; DMEM, Dulbecco’s modified Eagle’s medium;
FBS, fetal bovine serum; FTDP-17, frontotemporal dementia
and Parkinsonism linked to chromosome 17; GSK3, glycogen
synthase kinase 3; HEK293cells, human embryonic kidney
cells; mAb, monoclonal antibody; MW, molecular weight; NFT,
neurofibrillary tangles; pAb, polyclonal antibody; PBS, phosphatebuffered saline; PHF, paired helical filaments; SDS–PAGE,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis;
TTBK1, tau-tubulin kinase 1; TTBK1cat, catalytic domain of
recombinant TTBK1; TTK, tau-tubulin kinase.
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Noble et al. 2003), suggesting that up-regulation of tau
kinase can either cause or enhance tau aggregation.
In addition to such Ser/Thr residues, recent studies have
demonstrated that PHF-tau is also phosphorylated at Tyr
residues (Tyr18, 197 and 394 of 2N/4R tau) in the brain of
patients with AD (Lee et al. 2004; Bhaskar et al. 2005; Derkinderen et al. 2005; Vega et al. 2005) and in animal models of FTDP-17 (Lee et al. 2004; Bhaskar et al. 2005; Vega
et al. 2005). These findings suggested that not only Ser/Thr
phosphorylation but also Tyr phosphorylation of tau protein is involved in NFT formation. Yet, the way in which
Tyr phosphorylation of tau protein alters its affinity for aggregation has not yet been determined. Although the sarcoma family of nonreceptor tyrosine kinases (src)-like Tyr kinase family, e.g. Fyn and c-Abl, can phosphorylate Tyr18
and Tyr394 (Lee et al. 2004; Derkinderen et al. 2005), no
kinase has been reported to phosphorylate Tyr197. In addition, the known tau kinases are not specific to neurons
where some cell type-specific molecular mechanism should
exist for the PHF-tau and NFT formation.
Thus, the identification of a neuron-specific kinase,
which is involved in PHF-tau formation, will enhance
the understanding of the mechanism of NFT formation.
We have screened genes that are relatively specifically
expressed in human brain and have conserved protein
kinase domain and identified a neuron-specific kinase.
It has been deposited as tau-tubulin kinase 1 (TTBK1),
which encodes a Ser/Thr/Tyr protein kinase motif and a
polyglutamate region. Although the bovine homolog of
the protein has been characterized as a tau-tubulin kinase (TTK), the published mouse-homolog sequence
contained an error and was translated in a form truncated immediately after the kinase domain (Tomizawa
et al. 2001). Thus, there is no characterization of fulllength TTBK1. TTBK1 is highly homologous to TTBK2
and is among the closest relatives of casein kinase CK1
in the CK1 kinase group, which consists of the CK1,
TTBK and VRK families (Manning et al. 2002). CK1δ
is known to be up-regulated in AD brain and can induce
tau phosphorylation in vitro (Li et al. 2004), whereas
full-length TTBK2 has never been investigated. TTBK1
can directly phosphorylate tau protein in vitro and in intact cells at Ser198, Ser199, Ser202 and Ser422 sites.
TTBK1 also induces tau aggregation in SH-SY5Y cells.
Materials and methods
5’-RACE of TTBK1 cDNA
To find the 5’ end of the cDNA of the human TTBK1 gene, we employed a GeneRacer kit (Invitrogen, Carlsbad, CA, USA) with human cortex poly(A)+ RNA isolated by Trizol reagent (Invitrogen) and
the protocols supplied by the manufacturer. Reverse transcription was
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performed using a gene-specific primer 24289 (5’-TGGCCTCGATGGACTCCAAGATCTGCTT-3’). The cDNA product was subjected to
PCR using a set of PCR primers (GeneRacer 5’Primer and 24289; Invitrogen) and Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA,
USA). The PCR conditions were as follows: 2 min at 94°C, followed
by 25 cycles of 30 s at 94°C, 30 s at 65°C and 2 min at 72°C, with
15 min at 72°C and then held at 4°C. The PCR products were subjected to nested PCR using a set of primers (GeneRacer Nested 5’ Primer
and 24290: 5’-CAAGATCTGCTTGCCCAGCCGCAA-3’) using Pfu
Turbo. The PCR conditions were the same as described for the first
PCR. The resultant DNA bands were agarose-purified and cloned into
pCR4-TOPO vector using the TOPO Cloning kit (Invitrogen). The sequenced subcloned PCR fragments (named RACE500) corresponded
to the open reading frame (ORF) region of the KIAA1855 gene.
To generate full-length TTBK1, the RACE500 fragment from
the pCR4-TOPO vector was hybridized with an equimolar quantity
of vector containing KIAA1855 in pBluescript (Kazusa DNA Institute, Kisarazu, Chiba, Japan), followed by DNA polymerization using Herculase DNA polymerase (Stratagene) to generate a DNA template for the NH2 terminal of TTBK1. The PCR conditions were as
follows: 5 min at 94°C, followed by 10 cycles of 30 s at 94°C, 30 s
at 65°C and 5 min at 72°C, followed by 15 min at 72°C and then
held at 4°C. The fused RACE500/KIAA1855 template was subjected to PCR using a primer set (23266, 5’-GAAGTCCTTGAGCTCCGTCTC-3’; 25022, 5’-ACGCGTCGACATATGCAGTGCCTAGCGGCCGCCCTT-3’) and Herculase. The PCR conditions were as
follows: 2 min at 94°C, followed by 30 cycles of 30 s at 94°C, 30 s at
65°C and 2 min at 72°C), followed by 15 min at 72°C and then held
at 4°C. The resultant product was subjected to expression vector construction of full-length TTBK1. The entire sequence was confirmed
through DNA sequencing using a set of 15 primers.
Bioinformatic analysis
Amino acid sequences were obtained from KinBase (http://kinase.
com/kinbase/), and sequence alignments were obtained with the
ClustalW program (Thompson et al. 1994). The phylogenetic tree
was computed with ClustalW by the neighbor joining method with
Kimura’s correlation (bootstrap scores for 1000 iterations). The tree
was displayed using a TreeView program (Rogers et al. 1986). The
PESTfind program (http://bioweb.pasteur.fr/seqanal/interfaces/pestfind-simple.html) was used for the PEST sequence search.
Northern blot
The FirstChoice® human total RNA survey panel (Ambion, Autsin,
TX, USA) and human total RNA panel IV (BD Biosciences, San Jose,
CA, USA) were used for the northern blot analysis. The northern blot
was hybridized with a 32P-labeled cDNA probe derived from the 3’non-coding region of TTBK1 cDNA using DNA labeling beads (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer’s instructions. The membranes were exposed to Phosphoscreen, and
the images were scanned by Typhoon (Amersham Biosciences).
In situ hybridization
The location of mouse TTBK1 mRNA was determined on cryosections
(10 μm) of brain from adult C57/BL6 mice. For in vitro transcription,
the digoxigenin RNA-labeling kit (Roche Molecular Biochemicals, In-
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dianapolis, IN, USA) was used with pBluscript SK(–) vector (Stratagene) containing the 291-bp mouse TTBK1 PCR product cloned into
it’s XhoI-EcoRI sites as the template. Labeled probes, corresponding
to nucleotides 2400–2690 (counted from the ATG start codon), were
transcribed in either sense or antisense orientation, using either T7 or
T3 polymerases, respectively. The pre-hybridized sections were then
hybrizided with digoxigenin-labeled RNA probes, washed, incubated with alkaline phosphatase-conjugated anti-DIG Fab fragments
(Roche) and diluted to 1 : 500 following the manufacturer’s instructions (Roche). After washing with Tris-buffered saline, pH 9.0, sections were incubated overnight in substrate solution (nitro-blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate; Roche). The sections were
then counterstained with Hoechst 33342 (Invitrogen), and mounted
with Vectashield (Vector Laboratories, Burlingame, CA, USA). Phasecontrast and fluorescence microscopy were performed using a microscope (Eclipse TE300; Nikon Instruments, Melville, NY, USA) with
Plan Apo 2×/0.1, Plan-fluor ELWD 20×/0.45 and Plan-fluor ELWD
60×/0.70 objectives (Nikon) with a DVC-1310 digital camera and Cview imaging software (DVC Company, Austin, TX, USA).
Cell cultures
SH-SY5Y cells obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) were cultured in a 1 : 1 mixture of
Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 supplemented with 10% fetal bovine serum (FBS), 10 U/mL penicillin
and 10 μg/mL streptomycin (all reagents were purchased from Invitrogen). African green monkey kidney cells (COS-7) and human embryonic kidney cells (HEK293 cells) were cultured in DMEM supplemented with 10% FBS. Both types of cell cultures were grown in
a humidified 5% (v/v) CO2/air environment at 37°C.

1575
rification and quantification were performed using HEK293 cells and
CsCl ultracentrifugation as previously described (He et al. 1998).
The adenoviral vector encoding full-length human tau (Ad-htau40)
was a kind gift from Dr A. Takashima (Riken Brain Science Institute,
Wako-Shi, Saitama, Japan) (Sato et al. 2002). Adenoviral vector expressing green fluorescent protein (Ad-GFP) has been described in
detail elsewhere (Ikezu et al. 2003).
Recombinant protein purification
6×His-tagged TTBK1 kinase domain (amino acids 38–319, TTBK1cat) was subcloned into the NdeI-XhoI sites of the pET28a vector
(BD Biosciences) and transformed to BL21DE3 (BD Biosciences)
containing pG-Tf2 vector (TaKaRa; Mirus Bio, Madison, WI, USA),
which expresses TF and GroEL-GroES chaperone proteins. After 3 h
of incubation with 1 mm isopropyl thiogalactoside (dioxane-free;
Sigma, St Louis, MO, USA) at 37°C, cells were harvested, sonicated in lysis buffer (50 mm NaH2PO4, pH 8.0, 300 mm NaCl, 10 mm
imidazole, 1% Triton X-100, 20 mm 2-mercaptoethanol) containing
protease inhibitors and centrifuged at 40 000 g for 30 min in order to
collect supernatant. The recombinant protein was batch-purified from
the supernatant with Ni-NTA His Bind Resin (BD Biosciences), dialyzed against buffer A (20 mm Tris-HCl, pH 8.0 and 10% glycerol), and loaded onto HiTrap Q HP column (equilibrated in buffer A;
Amersham Biosciences) connected to a fast protein liquid chromatograph (ÄKTA FPLC system; Amersham Biosciences). The bound
protein was eluted with a 0–1.0 m gradient of NaCl. The fraction
containing eluted protein was concentrated using a centrifugal filter
device (Centricon YM30; Millipore Amicon, Bedford, MA, USA),
and dialyzed with storage buffer (20 mm Tris-HCl, pH 7.0, 250 mm
NaCl, 1 mm EGTA, 1 mm EDTA, 10 mm 2-mercaptoethanol, 50%
glycerol and 0.1% Triton X-100) for kinase assays.

Vector construction and transfection
The cDNA encoding the full length of TTBK1 (1321 amino acids) was
inserted into pcDNA3.1+ (Invitrogen) with synthetic linkers, which
fused an NH2-terminal influenza hemagglutinin protein (HA)-epitope
tag with a Kozac sequence (Kozak 1986). The full-length human tau
cDNA (htau40, the longest 2N/4R isoform kindly provided by Dr K.
Paudel, Sir Mortimer B. Davis-Jewish General Hospital, Montreal,
QC, Canada) was cloned into pcDNA3.1+. COS-7 cells were transiently transfected using FuGENE 6 (Roche) according to the manufacturer’s instructions. Forty-eight hours after transfection, cells were lysed
in Tris-buffered saline containing Triton X-100 (TBST) buffer (50 mm
Tris-Cl pH 7.4, 150 mm NaCl, 2 mM EDTA, 10% Glycerol and 1%
Triton X-100) containing phosphatase and protease inhibitors. Lysates
were centrifuged at 20 000 g. The supernatants, after the protein concentration was determined by a BCA assay kit (Pierce, Rockford, IL,
USA), were used for immunoblotting and immunoprecipitation.

In vitro protein kinase assay
The TTBK1 kinase domain fragment (TTBK1cat, 60 ng) was incubated with 500 ng of htau40 in 20 μL of kinase buffer (20 mm TrisHCl, pH 7.5, 100 μm ATP and 5 mm dithiothreitol) supplemented with 1 μCi [γ-32P]ATP (Amersham Biosciences) in the presence
of 10 mm of either MgCl2 or MnCl2 at 30°C for up to 2 h. All reactions were stopped by adding 10 μL of 2× Laemmli sample buffer and boiling for 5 min. Following sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), gels were stained with
Coomassie Brilliant Blue R-250 (CBB; FisherBiotech, Fairlawn, NJ,
USA) and dried for autoradiography. The radioactive bands were cut
from the gel and the radioactivity was quantified by a liquid scintillation counter (PerkinElmer, Wellesley, MA, USA). The kinetics
of the phosphorylation were analyzed using the best-fit program of
Prism v4 (GraphPad Software, San Diego, CA, USA).

Recombinant adenovirus
A recombinant adenovirus encoding HA-TTBK1-1321 (Ad-HATTBK1-1321) was constructed using the AdEasy system (He et al.
1998). HA-TTBK1 was excised from pcDNA3.1 using BamHI and
XbaI, and was directionally subcloned into the pShuttle-CMV at its
BglII and XbaI restriction sites. Successful recombinants of pShuttleCMV were transformed by electroporation along with the adenoviral
backbone vector pAdEasy-1 into BJ5183 cells. Viral production, pu-

Liquid chromatography/tandem mass spectrometry (LC/MS/MS)
Purified TTBK1cat (120 ng) was incubated with 1 μg of htau40 in
40 μL of kinase buffer in the presence of either 10 mm MgCl2 or
10 mm MnCl2 at 30°C overnight. The samples were separated by
SDS–PAGE and the stained bands were cut out and subjected to
LC/MS/MS analysis as described previously (Kayser et al. 2004).
Briefly, gel pieces were digested by trypsin (Promega, Madison,
WI, USA) and the digested peptides were extracted in 5% formic
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acid/50% acetonitrile and separated using C18 reversed phase LC
column (Dionex, Sunnyvale, CA, USA).
A Q-TOF Ultima tandem mass spectrometer (Waters, Milford,
MA, USA) with electrospray ionization was used to analyze the eluting peptides. The system was user-controlled employing the MassLynx software v3.5 (Waters) in data-dependant acquisition mode with
a 1-s survey scan (380–1900 D) followed by up to three, 2.4-s MS/
MS acquisitions (60–1900 D). The instrument was operated at a mass
resolution of 8000 and was calibrated using the fragment ion masses
of doubly protonated Glu-fibrinopeptides.
Database searches of the acquired MS/MS spectra were performed using Mascot v1.9.0 (Matrix Science, Manchester, UK). The
database was restricted to human proteins. The search parameters
were: no restrictions on either protein molecular weight or pI, enzymatic specificity was set to trypsin and phosphorylation was allowed
as a variable peptide modification. Only peptides that gave a Mascot
score greater than 13 (p < 0.05) for phosphorylated forms were considered as positive identifications.
Isolation of sarkosyl-insoluble Tau
Sarkosyl extracts were prepared as described previously (Goedert
et al. 1992) with slight modifications. Briefly, SH-SY5Y cells, infected with adenovirus (0.5 multiplicity of infection [MOI] of Ad-htau40
and 0–10 MOI of either Ad-HA-TTBK1-1321 or Ad-GFP), were homogenized in sucrose buffer (50 mm Tris-HCl, pH 7.4, 0.8 m NaCl,
1 mm EGTA and 10% sucrose) containing phosphatase and protease
inhibitors. The homogenates were centrifuged at 20 000 g for 20 min
at 4°C. The supernatants were mixed to a final concentration of 1%
sarkosyl and incubated for 1 h at 37°C with gentle shaking. After ultracentrifugation at 100 000 g for 60 min (TL-100; Beckman Coulter,
Fullerton, CA, USA), the sarkosyl-insoluble pellets were resuspended
in 2× Laemmli sample buffer for SDS–PAGE and immunoblotting.
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the transfected cells were fixed in 4% paraformaldehyde, and permeabilized in 0.1% Triton X-100 in phosphate-buffered saline (PBS). After blocking with 10% normal goat serum, the cells were incubated
with α-HA mAb (1 : 1000; Sigma) and 7589 pAb (1 : 300), followed
by incubation with either Alexa488- or Alexa594-conjugated secondary antibodies (Invitrogen), counterstained with Hoechst 33342 (Invitrogen), and mounted with Vectashield (Vector Laboratories) and cover
glass. Digital images were taken with a Nikon TE300 inverted fluorescence microscope (Nikon) using a Plan-fluor ELWD 40×/0.60 objective (Nikon) as previously described (Yamamoto et al. 2005).
A confocal laser-scanning microscopic study was performed using 4% paraformaldehyde-perfused mouse brain and 4% formalin-fixed human frontal cortex. Frozen sections (30-μm thick) were
chemically bleached to reduce autofluorescence following the method described by Sun et al. (2002), blocked with 10% normal goat serum containing 1% Triton X-100 in PBS, and incubated with primary antibodies, α-tubulin-β3 mAb (1 : 1000; Promega) and 7589 pAb
(1 : 300), followed by incubation with either Alexa488- or Alexa568conjugated secondary antibodies, counterstained with TOPRO-3 (Invitrogen) for nuclear staining, and mounted on glass slides as previously described (Yamamoto et al. 2005). The digital images were
captured with a Zeiss LSM410 and 100×/0.30 (oil objective; Carl
Zeiss AG, Göttingen, Germany).
Statistical analysis
All data were normally distributed. In case of multiple mean comparisons, data were analyzed by analysis of variances (anova), followed by the Newman–Keuls multiple comparison tests using statistics software (Prism v4.0; Graphpad Software). In the case of a single
mean comparison, data were analyzed by Student’s t-test. Values of p
less than 0.05 were regarded as significant.

Results
Immunoblot analysis and antibodies
Proteins were separated by SDS–PAGE, transferred to ImmobilonP membrane (Millipore Amicon), and blocked by blocking buffer
(SuperBlock with 5% skimmed milk; Pierce). The following antibodies (Abs) were used for immunoblotting: α-HA monoclonal
Ab (HA mAb, 1 : 10 000; Sigma); α-GFP mAb (1 : 3000; BD Biosciences); α-tau T46 mAb (specific to tau 404–441, 1 : 1000; Invitrogen); Tau-5 mAb (middle of tau, 1 : 1000; BD Biosciences);
AT8 (phospho-Ser199, Ser202 and Thr205 specific polyclonal Ab,
pAb, 1 : 500; Innogenetics, Gent, Belgium); CP13 mAb (phosphoSer202 specific, 1 : 250, a gift from Dr P. Davies, Albert Einstein
College of Medicine, Bronx, NY, USA); and pSer422 pAb (phospho-Ser422 specific, 1 : 1000, a gift from Dr A. Delacourte, Lille,
France). A TTBK1-specific rabbit polyclonal antiserum (7589 pAb)
was raised against a synthetic peptide, FDWEKAGTDALLST, of
TTBK1308–321 (Alpha Diagnostic Intl, San Antonio, TX, USA),
purified with a protein-G sepharose FF column (Amersham Biosciences) and used at 1 : 3000 (0.6 μg/mL).
Immunofluorescence and confocal laser-scanning microscopy
COS-7 cells (1 × 104/well) were plated on poly-d-Lysine-coated 8-well
LAB-TEK chamber slides (Nunc, Rochester, NY, USA) and transfected with pcDNA3.1-HA-TTBK1 using FuGENE 6 (Roche). After 48 h

Structure of the human TTBK1 gene
We isolated the full-length cDNA by 5’ rapid amplification
of cDNA ends based on the human KIAA1855 gene. This
cDNA was identical to the tau-tubulin kinase 1 (TTBK1)
derived from an automated computational analysis ‘kinome’ project (Manning et al. 2002). TTBK1 is located on
human chromosome 6p21.1 and is composed of 14 exons and 15 introns with a cDNA length of 6932 bp. The
TTBK1 protein is 1321 amino acids in length, has a kinase
domain, and a unique polyglutamate domain in the middle
region of the sequence (Fig. 1a). Human TTBK1 homologs
were found in mice, Caenorhabditis elegans and Drosophila melanogaster, the shorter non-catalytic regions of which
are non-homologous to human TTBK1 (Fig. 1a).
Phylogenetic tree analysis among the CK1 group,
which consists of CK1, TTBK and VRK families,
showed that TTBK1 is highly homologous to TTBK2
(Fig. 1b). Among the CK1 group, CK1δ can phosphorylate tau in vitro and in cultured cells (Li et al. 2004). The
alignment of the kinase domain of TTBK1 and CK1δ
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Figure 1. Multiple sequence alignment with tau-tubulin kinase 1
(TTBK1) and its orthologues. (a) Alignment of human and mouse
TTBK1, and Caenorhabditis elegans and Drosophila melanogaster
TTBK (KinBase ID: 16054, 11247, 11973 and 9447, respectively).
TTBK1 34–308, dual-kinase domain; 309–732, conserved domain
A; 733–770, polyglutamate domain; 771–1308, conserved domain B.
Numbers in the diagrams are the percentage homology and similarity

in parenthesis to human TTBK1. (b) Phylogenetic tree of the human
casein kinase (CK) family using clustal W and TreeViewer programs.
The scale bar represents 0.1 amino acid substitution per site. Bootstrap values (1000 bootstrap iterations) are indicated. Vaccinia related kinase 3 (VRK3) was removed because of its low homology to
other kinases in the CK1 group. (C) The comparison of catalytic domains of TTBK1 and human CK1δ (KinBase ID: 14657).

showed a modest identity of 38% (52% homology,
Fig. 1c). These results suggest that TTBK1 is the closest
relative of CK1, but not a member of CK1 family.

rons (Figs 2e and f). The control sense probe showed no
hybridization, and the TTBK1 probe did not cross-react
with TTBK2 (data not shown). These data suggest the
expression of the TTBK1 gene is specific to neurons.

Characterization of TTBK1 mRNA and protein expression
To determine the distribution of the TTBK1 gene, northern
blotting of a multiple human tissue panel was conducted
using a probe for human TTBK1(Fig. 2a). TTBK1 mRNA
was detected as a 7.5-kb mRNA band in adult brain cortex and cerebellum (lanes 1 and 2) and fetal brain tissue
(lane 23, arrow). This is similar to the sequence length of
human TTBK1, confirming its brain specificity from the
fetal stage. In addition, a weak expression of TTBK1 was
detected in both the spinal cord and testis in an image obtained with longer exposure (data not shown). No significant expression was detected in any of the other tissues.
In situ hybridization of mouse brain was performed
to determine the distribution of TTBK1 gene expression
in the brain. The cortical layers, the CA1 layers of the
hippocampus, and the granular layer of cerebellum were
strongly labeled with the mouse TTBK1 complementary RNA (cRNA) probe (Figs 2b–f). Signals were also
observed in the perinuclear and cytoplasmic regions of
the large cortical pyramidal cells in the temporal cortex
(Fig. 2b). Signals were also seen in the CA1 pyramidal
neurons (Figs 2c and d) and cerebellum granular neu-

TTBK1 protein expression in neurons
To detect the expression of TTBK1 protein, we prepared a rabbit polyclonal antibody (7589 pAb) raised
against a synthetic peptide corresponding to the residues 308–321 of TTBK1 that are conserved in both
humans and mice (see Materials and methods). The
specificity of 7589 has been confirmed by both immunoblotting and immunocytochemistry (Fig. 3).
Frozen sections of human and mouse cortex were
probed with antibodies to a neuronal marker, tubulinβ3 (Figs 4a, d, e, f, i and j in green), and 7589 (Figs 4b,
d, e, g, I and j in red) for confocal laser-scanning microscopic imaging. The 7589-immunoreactive cells
were mainly co-localized with tubulin-β3-positive neurons in human (Figs 4a–d, arrowheads) and mouse cortex (Figs 4e–h, arrowheads), and the immunoreactivity was diminished by pre-incubation of 7589 with the
antigen peptide (data not shown). These data indicated
that TTBK1 is present in neurons.
To determine the actual molecular weight (MW) of
TTBK1, HA- and myc-tagged full-length TTBK1 (HATTBK1) was expressed in COS-7 cells and detect-
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Figure 2. Tissue distribution of TTBK1
mRNA and its protein expression.
(a) Northern blot of human multiple tissue total RNA panel for tau-tubulin kinase 1 (TTBK1) mRNA. The arrow points
to a specific TTBK1 mRNA band (7.5 kb)
in the brain and the cerebellum (upper
panel). Ethidium bromide staining of 28S
rRNA (lower panel). (b–f) In situ hybridization of TTBK1 mRNA. (b) Coronal sections of adult mouse brain probed with
mouse TTBK1 antisense complementary
RNA. Mouse TTBK1 mRNA expression is
observed in the frontal cortical layers (II–
VI) and CA1 region of the hippocampus.
CC, corpus callosum. (c) The CA1 region
of the hippocampus. (d) Magnification
of the inset in (c); the pyramidal layer of
CA1. (e) Granular layer of the cerebellum.
(f) Magnification of the inset in (e). Scale
bars: (b) 100 μm; (c and e), 200 μm; (d
and f), 50 μm.

Figure 3. Immunofluorescent staining of tau-tubulin kinase 1 (TTBK1)
by 7589 in transfected cells. (a–h) The detection of HA-TTBK1 by
7589 polyclonal antibodody (pAb) in COS-7 cells by double-immunostaining with anti-HA monoclonal antibody (mAb) (a and e, green) and
7589 pAb (b and f, red). Pre-absorption of 7589 pAb with the synthet-

ic antigen peptide resulted in a reduction of staining (f), demonstrating
the specificity of the observed signals. Cell nuclei were counterstained
with Hoechst 33342 (c and g, blue). (d) and (h) present merged images. Scale bars in panels (d) and (h) represent 50 μm.
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Figure 4. Immunofluorescence and immunoblotting of tau-tubulin kinase 1 (TTBK1). (a–j) Immunofluorescence of TTBK1 in brain tissues.
Confocal images of human and mouse cortex double-stained with antitubulin-β3 (a, d, e, f, i and j, green) and 7589 (b, d, e, g, i and j, red).
The cell nuclei were counterstained with TO-PRO-3 (c, d, e, h, i and j,
blue). The arrowheads indicate co-localization of tubulin-β3 and 7589
immunoreactivity in cortical neurons. (d) and (i); merged images of (a–
c) and (f–h), respectively. (e) and (j), a higher magnification of the areas specified in (d) and (i), respectively. Scale bars: (d) and (i), 25 μm;
(e) and (j), 10 μm. (k) COS-7 cells expressing either HA-TTBK1-1321
or Mock vector were treated with different concentrations of chloroquine (Cq; 10, 50 and 100 mm) for 24 h and samples were probed

with anti-HA monoclonal antibody (mAb). Arrow, 230-kDa band; arrowhead, 100-kDa band. (l) Detection of TTBK1 in mouse cortical extracts
(150 μg) and COS-7 lysate expressing HA-TTBK1 (positive control)
using anti-TTBK1 rabbit polyclonal antibody (pAb, 7589). Arrowhead,
100-kDa band of mouse TTBK1 and HA-TTBK1; *, proteolyzed HATTBK1 bands. (m) Autophosphorylation activity of TTBK1 in vitro. Immunoprecipitation of HA-TTBK1 expressed in COS-7 cells 24 h after
treatment either with or without 50 μm Cq using anti-HA mAb (upper panel). Autoradiography of in vitro kinase assay using immunoprecipitated TTBK1 and [γ-32P]ATP (lower panel). Arrows and arrowheads indicate full-length TTBK1 ( 230 kDa) and processed TTBK1
(100 kDa), respectively

ed using anti-HA antibody, which labeled two bands
at 100 kDa and 230 kDa (Fig. 4k, lane 1, arrowhead
and arrow, respectively). Because the predicted MW of
TTBK1 is 142.7 kDa, it is possible that the full-length
TTBK1 migrates to 230 kDa because of the negative
charge of the polyglutamate sequence and the protein
modification, and the 100-kDa band is its proteolytic
fragment resulting from protein processing.
To test this possibility, cells were incubated with chloroquine (Cq), a lysosomal inhibitor. Cq treatment increased

the quantity of the 230-kDa band with a corresponding reduction in the 100-kDa protein in a dose-dependent manner
(Fig. 4k, lanes 2–4). This suggests that the 100-kDa band is
a lysosomal degradation product of full-length TTBK1.
To examine the endogenous expression of TTBK1 in
mouse brain, we used the 7589 pAb for immunoblotting
(Fig. 4l). The antibody detected a 100-kDa band in mouse
cortex and HA-TTBK1 expressed in HEK293 cells, but
not in mock-transfected cells (Mock, Fig. 4l). The MW
shift is caused presumably by the tagging of TTBK1 with
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HA and myc. The absence of a 230-kDa protein in the
mouse cortex suggests a very small quantity of full-length
TTBK1 as compared with the 100-kDa fragment.
To verify that the 100- and 230-kDa TTBK1 have
kinase activity, HA-TTBK1 was expressed in COS-7
cells treated in either the absence or the presence of Cq
and immunoprecipitated by anti-HA antibody. The immunoprecipitated 230- and 100-kDa fragments underwent autophosphorylation as determined by the autoradiogram of incorporated [32P]O4 (Fig. 4m, arrows and
arrowheads, respectively), confirming that both TTBK1
forms exhibit kinase activity.
TTBK1 phosphorylates tau protein in vitro
We investigated whether the kinase catalytic domain of
recombinant TTBK1 (TTBK1cat) can directly phosphorylate tau protein in vitro. Initial attempts to purify recombinant full-length TTBK1 from either Escherichia coli
or baculovirus-infected sf9 insect cells were unsuccessful because of the insolubility of TTBK1. E. coli-purified
TTBK1cat and 6×His-tagged human tau protein (htau40)
migrate at 43 and 70 kDa with purity greater than 90%,
as shown by the Coomassie Brilliant Blue staining of
the protein (Fig. 5b, left-hand panel). We tested a panel
of free metals to phosphorylate 6×His-tagged human tau
protein by TTBK1cat. Mg2+ and Mn2+, but not K+, Ca2+
or Zn2+, conditions activated TTBK1cat (data not shown).
The timecourse study showed that the incorporation of 32P

Figure 5. Tau phosphorylation by tau-tubulin kinase 1 (TTBK1) in vitro.
(A) Representative kinetics of htau40 phosphorylation. (Upper panels)
Autoradiography of 32P-incorporated htau40 by the catalytic domain
of recombinant TTBK1 (TTBK1cat) in the presence of 10 mm MgCl2,
MnCl2 or no metal from 0 to 120 min. (Graph) Phosphotransfer to
htau40 in the presence of MnCl2 ( ), MgCl2 (□) or no metal (○). Data
were fitted to a hyperbola of GraphPad Prism v4.0. Error bars represent SD of three samples. (b) (Left-hand panel) Left lane: pre-stained
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into tau by TTBK1cat is faster in the presence of Mn2+
than in the presence of Mg2+ (Fig. 5a, 1.2 and 2.2 mol of
phosphate transfer/mol of tau in the Mg2+ and Mn2+ conditions, respectively). The specific activity of TTBK1cat
was 0.26 and 0.57 μmol/mg/min in the presence of Mg2+
and Mn2+, respectively. The incubation of htau40 with
TTBK1cat caused a greater reduction in the electrophoretic mobility of htau40 than with htau40 incubated without
TTBK1cat (Fig. 5b, right-hand panel). These data suggest
that TTBK1cat directly induced phosphorylation and the
electrophoretic mobility shift of htau40 in vitro.
Identification of phosphorylated amino acid of tau
by tandem mass spectrometry
We determined the exact htau40 phosphorylation sites in vitro by phosphopeptide mapping using liquid chromatography and tandem mass-spectrometry (LC/MS/MS). The LC/
MS/MS data covered 71% of the recombinant htau40 sequence, and the possible phosphorylation sites are listed in
Table 1. Both Mg2+ and Mg2+ conditions identified htau40
phosphorylation at Tyr197, Ser198, Ser199, Ser202 and
Ser422 sites, which have all been reported to be phosphorylated in PHF-tau (Iqbal et al. 1989; Morishima-Kawashima et al. 1995a,b; Hanger et al. 1998; Vega et al. 2005).
Ser416 and Thr427 are new sites, and Thr427 phosphorylation was observed under both Mg2+ and Mn2+ conditions.
These results suggest that TTBK1 is a critical enzyme for
the phosphorylation of PHF-specific sites of tau protein.

molecular marker. Right lane: Coomassie Brilliant Blue R-250 staining
of purified 6×His-tagged TTBK1cat (43 kDa; see Materials and methods for the purification procedure) and 6×His-tagged htau40 (70 kDa,
purchased from Calbiochem). (Right panel) Immunoblotting of total
htau40 (50 ng) using T46 monoclonal antibody (mAb) after overnight
incubation either with or without TTBK1cat (50 ng) with 10 mm MnCl2.
Arrowhead, original molecular weight of htau40.
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TTBK1 induces multiple tau phosphorylation and
aggregation
To test whether the tau phosphorylation sites identified
by phosphopeptide mapping are actually phosphorylated
by full-length TTBK1 in tissue-cultured cells, htau40 and
full-length HA-TTBK1 were transiently co-expressed in
COS-7 cells for immunoblotting analysis (Fig. 6a). Detection of total tau protein using the tau antibody T46,
the reactivity of which is phosphorylation independent
(Kosik et al. 1988), revealed a substantial electrophoretic mobility shift of tau induced by TTBK1 expression (Fig. 6a, right-hand upper panel). Co-expression of
htau40 and TTBK1 resulted in multiple tau phosphorylations as detected by specific antibodies, AT8 (Ser199,
Ser202 and Thr205 specific), CP13 (Ser202 specific) and

pS422 (Ser422 specific). Thus, the htau40 phosphorylation by TTBK1 at Ser199, Ser202 and Ser422 were confirmed both in vitro and in intact cell systems. Importantly, pS422 is a PHF-tau specific antibody (Hasegawa
et al. 1992; Zheng-Fischhofer et al. 1998). We could not
detect Tyr-phosphorylation of htau40 by using anti-phospho-Tyr antibodies (PY20, 4G10 and rabbit polyclonals,
data not shown). This could be caused by the presence
of negatively charged either phospho-Ser198 or phospho-Ser199, which might interfere with the interaction
of phospho-Tyr197 with anti-phospho-Tyr antibodies.
Because tau phosphorylation is closely related to its
aggregation, we investigated whether the over-expression
of TTBK1 induced htau40 aggregation in human neuronal cells (SH-SY5Y, Fig. 5b). Co-infection of SH-SY5Y

Figure 6. Tau-tubulin kinase 1 (TTBK1)-induced tau phosphorylation
and aggregation in cultured cells, and its expression in the Alzheimer’s
disease (AD) brain. (a) Phosphorylation of htau40 by HA-TTBK1 in
COS-7 cells. (Left-hand panel) HA-TTBK1 bands at 230 and 100 kDa
are indicated by an arrow and an arrowhead, respectively. (Right-hand
panels) Detection of total htau40 (T46), its phosphorylation at Ser199,

Ser202 and Thr205 (AT8), Ser202 (CP13) and Ser422 (pS422).
(b) Tau aggregation induced by TTBK1 expression in SH-SY5Y human
neuroblastoma cells. Sucrose supernatant protein samples were run
on SDS–PAGE and immunoblotted using anti-HA (TTBK1), anti-GFP
and Tau-5, respectively. Sarkosyl-insoluble (SI) fractions were immunoblotted using Tau-5.
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cells with adenovirus expressing wild-type htau40 and
increasing titer of adenovirus expressing HA-TTBK1 resulted in a reduction of sucrose supernatant htau40 (Sup)
and the accumulation of a sarkosyl-insoluble fraction of
htau40 (Sarkosyl insoluble; Fig. 6b). Control co-infection
with an increasing titer of GFP-expressing adenovirus
had no effect on tau aggregation. These data demonstrated that TTBK1 significantly increased the tau insolubility in human neuronal cells. These data support the idea
that TTBK1 is involved in tau phosphorylation and aggregation in an intact cell system.
Discussion
TTBK1 is a unique protein because it has dual kinase activity on human tau protein and is specifically expressed
in neurons. The tissue and brain specificity of TTBK1 expression has been confirmed by northern blotting, in situ
hybridization and immunohistochemistry of human and
mouse brains using specific 7589 pAb against TTBK1.
The expression of HA-tagged full-length TTBK1 was
mainly cytoplasmic, which is consistent with its endogenous, neuron-specific expression in human and mouse
cortex. We have also confirmed two distinct fragments
of TTBK1 when expressed in COS-7 cells. The discrepancy in the predicted molecular weight (142 kDa) and
apparent size (230 kDa) of full-length TTBK1 on SDS–
PAGE could be a result of either multiple phosphorylations of TTBK1 or the negative charge of the polyglutamate domain. Similar abnormal migration was found in
middle MW neurofilaments (NF-M), which also contain
a polyglutamate domain and have multiple phosphorylation sites (Napolitano et al. 1987). This discrepancy requires further analysis either by treating the protein sample with protein phosphatase or through deleting the
polyglutamate region of TTBK1 to see if these manipulations alter the electrophoresis of the TTBK1 protein.
TTBK1 appears to undergo a post-translational modification by limited lysosomal processing to generate a 100kDa fragment, which contains the dual kinase domain and
non-catalytic region. This is specific to lysosomes as Cq, a
lysosomal inhibitor, blocked endoproteolysis and MG132,
a potent proteasome inhibitor, had no effect on the accumulation of a full-length TTBK1 (data not shown). Interestingly, TTBK1 has seven possible PEST sequences,
which are defined as hydrophilic stretches of amino acids
either greater than or equal to 12 residues in length, which
contain at least one Pro, one Glu or Asp, and one Ser or
Thr (Rechsteiner and Rogers 1996). The PESTfind program identified amino acids 436–447, 528–541, 553–575,
626–640, 819–834, 1003–1036 and 1119–1144 as possible PEST sequences (Rogers et al. 1986). Whether the
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putative PEST sequences of TTBK1 are functional and
required for the lysosome-mediated degradation will be
explored in future studies. Currently under investigation
is whether the polyglutamate region remains in the 100kDa form. We have also detected an endogenous 100-kDa
form of TTBK1 in mouse brains, which is also found in
SH-SY5Y cells (data not shown).
Fyn and c-Abl have been reported to phosphorylate
tau protein at Tyr18 and Try394, respectively (Lee et al.
2004; Derkinderen et al. 2005). TTBK1 is the first kinase
that can directly phosphorylate Tyr197 in vitro, although
we could not confirm it in an intact cell system. Among
other TTBK1-mediated phosphorylation sites, Ser422
is of particular interest because it appears to be highly
specific for PHF-tau (Hasegawa et al. 1996; Zheng-Fischhofer et al. 1998), and is critically involved in tau aggregation in SH-SY5Y cells (Pennanen and Gotz 2005).
In addition to phosphorylation, TTBK1 induces
htau40 aggregation in SH-SY5Y cells. A reduction of
the sucrose supernatant fraction of htau40 is correlated
with the accumulation of the sarkosyl-insoluble fraction,
demonstrating that the majority of htau40 is in the insoluble fraction by TTBK1 expression. TTBK1 phosphorylates residues critical for tau aggregation in SH-SY5Y
cells (Ser202 and Ser422, among others; Pennanen and
Gotz 2005), demonstrating that TTBK1 activation enhances tau aggregation through its phosphorylation.
In summary, TTBK1 is a brain-specific protein kinase, specifically expressed in neuronal cells, phosphorylates tau protein at multiple PHF-tau-related residues in vitro and in intact cell systems, and induces
tau aggregation. TTBK1 may play an important role
in neural tau phosphorylation and aggregation. Further
studies are necessary to elucidate the molecular mechanism of TTBK1 expression, processing, activation and
intracellular signaling in neurons.
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